HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Dysregulation of IL-2 and IL-7 homeostasis persists in CD4<sup>+</sup>T cell subsets irrespective of presence or absence of viremia or antiretroviral therapy in HIV infection.
|
30744575 |
2019 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
We showed that HIV infection significantly reduced the proportion of Th2 (interleukin 4 [IL-4]/IL-5/IL-13) producing <i>M. tuberculosis</i>-specific CD4 T cells and IL-2-producing <i>M. tuberculosis</i>-specific CD4 and CD8 T cells in individuals with LTBI or PTB (<i>P < </i>0.05).
|
30541853 |
2019 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we revisited the role of IL-2 in HIV infection and investigated whether its use as an adjuvant with therapeutic vaccination, impacts on HIV-specific responses.
|
28708863 |
2017 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
We found 1) a constitutively lower frequency of IL-2+ and IFN-γ+ T cells in the CHR group compared with the HIV, CO and healthy groups; 2) a suppressive activity of soluble T. cruzi antigen, which down-regulated IL-2+CD4+ and IFN-γ+CD4+ phenotypes, notably in the healthy group; 3) a down-regulation of inflammatory cytokines on CD8+ T cells in the indeterminate form of Chagas disease; and 4) a significant increase in IL-10+CD8+ cells distinguishing the indeterminate form from the cardiac/digestive form of Chagas disease, even in the presence of HIV infection.
|
29236910 |
2017 |
HIV Infections
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This variant genotype may also be associated with reduced circulating IL-2 levels and thus reduced pro-inflammatory response in normotensive women, which may be further influenced by the presence of HIV infection and HAART.
|
28103790 |
2017 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
In vitro, the IL-2 signaling pathway and IL-2-dependent cell cycle induction are essential for HIV infection of stimulated T cells.
|
27384654 |
2016 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
These data identify a novel miR-9/Blimp-1/IL-2 axis that is dysregulated in progressive HIV infection.
|
23129528 |
2013 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
These results extend previous data on the role of Treg in HIV infection by filling the gap between expansion of Treg/CD39+ in HIV infection and the suppression of CD4+ T-cell function through inhibition of IL-2 production.
|
23658513 |
2013 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, IL-2 production was associated with expression of CD25, and neutralization of IL-2 completely abrogated productive HIV infection in vitro.
|
21115690 |
2010 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-2 therapy in patients with HIV infection.
|
19828532 |
2009 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
In contrast, PHA/IL-2, which is widely used to prime cells for HIV infection, takes 2-3 days.
|
18364393 |
2008 |
HIV Infections
|
0.400 |
Biomarker
|
group |
LHGDN |
These findings suggest that in lymphoid tissues, endogenous soluble factors, likely including IL-2 and -15 and others, stimulate the formation of high molecular mass A3G complexes in tissue-resident naive CD4 T cells, thereby relieving the potent postentry restriction block for HIV infection conferred by low molecular mass A3G.
|
16606671 |
2006 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ T cell proliferation in HIV infection.
|
16847956 |
2006 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
|
12924540 |
2003 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, these findings point to a role for IL-2 in inducing virus purging from dendritic cell reservoirs but indicate no relevant potential of the cytokine in restoring defective elements of innate immunity in HIV infection.
|
12699419 |
2003 |
HIV Infections
|
0.400 |
Biomarker
|
group |
CTD_human |
Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment.
|
12878215 |
2003 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
The significance of these results and those from other studies on the use of IL-2 in HIV disease are discussed.
|
11564594 |
2001 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection.
|
8695805 |
1996 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture-induced down-modulation of Bcl-2.
|
8892656 |
1996 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
In preliminary studies, intermittent infusions of interleukin-2 led to increases in CD4 counts in patients with human immunodeficiency virus (HIV) infection and more than 200 CD4 cells per cubic millimeter.
|
8857018 |
1996 |
HIV Infections
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The striking difference in the effect of HIV infection on the expression of IFN-gamma and IL-2 genes indicates that these cytokines are under separate control.IL-4 mRNA levels were not changed.
|
8409454 |
1993 |
HIV Infections
|
0.400 |
Biomarker
|
group |
BEFREE |
The impaired in vitro production of interleukin-2 in HIV infection is negatively correlated to the number of circulating CD4+DR+ T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation.
|
8500265 |
1993 |
HIV Infections
|
0.400 |
AlteredExpression
|
group |
BEFREE |
No evidence was obtained suggesting abnormal regulation of the TCGF or of the IFN-gamma gene consequent to HTLV-III infection.
|
3001715 |
1985 |